Cellectis (CLLS) Stock Price, News & Analysis

Company Overview

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Key Stats

• Today's Range: $1.41 to $1.47
• 50-Day Range: $1.15 to $1.65
• 52-Week Range: $1.10 to $2.81
• Volume: 103,936 shs
• Average Volume: 143,348 shs
• Market Capitalization: $80.43 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.00
• Consensus Rating: Buy

Cellectis Stock Analysis - MarketRank™

Cellectis scored higher than 63% of companies evaluated by MarketBeat, and ranked 375th out of 930 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Cellectis has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Cellectis has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Cellectis are expected to decrease in the coming year, from ($0.46) to ($0.52) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Cellectis is -1.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cellectis is -1.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Cellectis has a P/B Ratio of 0.95. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.47% of the float of Cellectis has been sold short.

Short Interest Ratio / Days to Cover

Cellectis has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cellectis has recently decreased by 30.74%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cellectis does not currently pay a dividend.

Dividend Growth

Cellectis does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.47% of the float of Cellectis has been sold short.

Short Interest Ratio / Days to Cover

Cellectis has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cellectis has recently decreased by 30.74%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.9 / 5
• News Sentiment: 0.37

News Sentiment

Cellectis has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.87 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Cellectis this week, compared to 1 article on an average week.

Search Interest

Only 3 people have searched for CLLS on MarketBeat in the last 30 days. This is a decrease of -73% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Cellectis insiders have not sold or bought any company stock.

Percentage Held by Insiders

16.41% of the stock of Cellectis is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

63.90% of the stock of Cellectis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

CLLS Stock Analysis - Frequently Asked Questions

How have CLLS shares performed this year?

Cellectis' stock was trading at $1.80 at the start of the year. Since then, CLLS stock has decreased by 19.6% and is now trading at $1.4470.
View the best growth stocks for 2025 here.

How were Cellectis' earnings last quarter?

Cellectis S.A. (NASDAQ:CLLS) issued its quarterly earnings data on Monday, May, 12th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.15) by $0.03. The biotechnology company earned $12.03 million during the quarter, compared to analysts' expectations of $12.71 million. Cellectis had a negative net margin of 234.39% and a negative trailing twelve-month return on equity of 74.55%.

When did Cellectis IPO?

Cellectis (CLLS) raised $129 million in an initial public offering (IPO) on Wednesday, March 25th 2015. The company issued 3,500,000 shares at a price of $36.83 per share. BofA Merrill Lynch, Jefferies and Piper Jaffray served as the underwriters for the IPO and Oppenheimer was co-manager.

Who are Cellectis' major shareholders?

Top institutional investors of Cellectis include UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC (8.50%), Long Focus Capital Management LLC (8.49%), Baillie Gifford & Co. (0.25%) and Acadian Asset Management LLC (0.08%).

How do I buy shares of Cellectis?

Shares of CLLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Cellectis own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cellectis investors own include Invesco QQQ (QQQ), SPDR S&P 500 ETF Trust (SPY), SPDR Dow Jones Industrial Average ETF Trust (DIA), NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU) and Alibaba Group (BABA).

Company Calendar

• Last Earnings: 5/12/2025
• Today: 5/31/2025
• Next Earnings (Estimated): 8/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CLLS
• CIK: 1627281
• Web: www.cellectis.com
• Phone: (318) 169-1600
• Fax: 33-1-81-69-16-06
• Employees: 290
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $7.00
• High Stock Price Target: $10.00
• Low Stock Price Target: $4.00
• Potential Upside/Downside: +383.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.86)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$101.06 million
• Net Margins: -234.39%
• Pretax Margin: -235.80%
• Return on Equity: -74.55%
• Return on Assets: -22.65%

Debt

• Debt-to-Equity Ratio: 0.48
• Current Ratio: 1.78
• Quick Ratio: 1.78

Sales & Book Value

• Annual Sales: $47.63 million
• Price / Sales: 1.69
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.52 per share
• Price / Book: 0.95

Miscellaneous

• Outstanding Shares: 55,584,000
• Free Float: 46,463,000
• Market Cap: $80.43 million
• Optionable: Optionable
• Beta: 3.11